{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:15:01Z","timestamp":1788336901080,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["beva.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Equine Veterinary Journal"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intra\u2010articular (IA) corticosteroids can cause hyperinsulinemia, which can subsequently increase the risk of laminitis, particularly in horses with insulin dysregulation (ID). Sodium glucose cotransporter 2 inhibitors (SGLT2i), a drug class that is being utilised more commonly in horses with insulin dysregulation, could potentially be used to control post\u2010IA corticosteroid hyperinsulinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether treatment with the SGLT2i drug ertugliflozin decreases hyperinsulinemia following intra\u2010articular corticosteroid administration in metabolically normal horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Prospective, controlled, cross\u2010over study design. Eight mixed\u2010breed, metabolically normal geldings either received no treatment (CTL) or were treated with ertugliflozin (ERT) for 7\u2009days before and 7\u2009days after a total dose of 18\u2009mg of IA triamcinolone acetonide (TA). Samples for resting glucose and insulin concentrations, as well as dynamic oral sugar testing (OST), were collected. Treatments were crossed over and the study repeated. Two\u2010way, repeated measures analysis of variance was used to identify timepoint by treatment differences (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Insulin was significantly lower 2\u2009days after IA TA with ERT treatment at 60\u2009min post\u2010OST. Resting glucose concentrations were significantly lower with ERT treatment at 8\u2009h, 12\u2009h, 24\u2009h, and 48\u2009h while resting insulin concentrations were significantly lower with ERT treatment at 12\u2009h, 24\u2009h, 48\u2009h, and 72\u2009h post\u2010IA injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Limitations<\/jats:title>\n                    <jats:p>Non\u2010insulin dysregulated horses and compounded ertugliflozin were utilised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with ertugliflozin decreases glucose and insulin changes following IA corticosteroid administration in metabolically normal horses. Further investigation of this treatment strategy in insulin dysregulated horses is warranted as it may reduce hyperinsulinemia and, therefore, the risk of laminitis with IA corticosteroid administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/evj.70150","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T03:31:09Z","timestamp":1770003069000},"page":"1372-1379","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with ertugliflozin mitigates the hyperinsulinemic response to intra\u2010articular triamcinolone acetonide"],"prefix":"10.1002","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-9230","authenticated-orcid":false,"given":"Allen E.","family":"Page","sequence":"first","affiliation":[{"name":"Maxwell H. Gluck Equine Research Center University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4885-3220","authenticated-orcid":false,"given":"Jenna L.","family":"McPeek","sequence":"additional","affiliation":[{"name":"Maxwell H. Gluck Equine Research Center University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"McGreevy","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine Lincoln Memorial University  Harrogate Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Carattini","sequence":"additional","affiliation":[{"name":"Maxwell H. Gluck Equine Research Center University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-0708","authenticated-orcid":false,"given":"Emma N.","family":"Adam","sequence":"additional","affiliation":[{"name":"Maxwell H. Gluck Equine Research Center University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.13489"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.14003"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jevs.2025.105404"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ani14152250"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.13899"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1388470"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.72.9.1234"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.67.4.654"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.253.4.470"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-019-1811-2"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203655"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.13975"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.13738"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2024.106894"},{"key":"e_1_2_13_16_1","unstructured":"HartK BertinF\u2010R DurhamA FrankN McGowanCM SchottHC et al.Recommendations for the diagnosis and treatment of pituitary pars intermedia dysfunction (PPID) Equine Endocrinology Group.2023[accessed 2025 May 6]. Available from:https:\/\/equineendocrinologygroup.org\/s\/2023\u2010EEG\u2010PPID\u2010Digital\u2010version\u2010with\u2010insert\u201012222023.pdf"},{"key":"e_1_2_13_17_1","unstructured":"BertinF\u2010R BaileyS BurnsT deLaatM DurhamA FrankN et al.Recommendations for the diagnosis and Management of Equine Metabolic Syndrome (EMS) and insulin dysregulation Equine Endocrinology Group.2024[accessed 2025 May 6]. Available from:https:\/\/equineendocrinologygroup.org\/s\/Final-Oct-2024-EEG-EMS-ID-Recommendations.pdf"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.1983.tb01826.x"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2008.02.029"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1436714"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2020.106476"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jevs.2021.103770"},{"key":"e_1_2_13_23_1","unstructured":"OpenEpi[accessed May 2025 6].\u00a0Available from:https:\/\/www.openepi.com\/Power\/PowerMean.htm."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16906"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.5455\/OVJ.2022.v12.i4.14"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.14071"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.13470"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/eve.13924"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.13476"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2025.106412"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15423"},{"key":"e_1_2_13_32_1","unstructured":"AllenLV BassaniGS ElderEJ ParrAF.Strength and Stability testing for compounded preparations.2015[accessed 2025 Nov 4]. Available from:https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/FAQs\/strength-stability-testing-compounded-preparations.pdf"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203343"}],"container-title":["Equine Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/evj.70150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/evj.70150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/evj.70150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:12:41Z","timestamp":1786079561000},"score":1,"resource":{"primary":{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/10.1002\/evj.70150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/evj.70150"],"URL":"https:\/\/doi.org\/10.1002\/evj.70150","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.175570761.12259367\/v1","asserted-by":"object"}]},"ISSN":["0425-1644","2042-3306"],"issn-type":[{"value":"0425-1644","type":"print"},{"value":"2042-3306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"2025-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}